Umbilical Cord Mesenchymal Stem Cells Therapy (19#iSCLife®-SA) for Patients With Spinocerebellar Ataxia
A Clinical Research on the Safety/Efficacy of Umbilical Cord Mesenchymal Stem Cells Therapy for Patients With Spinocerebellar Ataxia
Sponsor: Sclnow Biotechnology Co., Ltd.
This observational or N/A phase trial investigates Spinocerebellar Ataxia Type 1 and Spinocerebellar Ataxia Type 2 and is currently actively recruiting participants. Sclnow Biotechnology Co., Ltd. leads this study, which shows 16 recorded versions since 2026 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Study Description(click to expand)This is a random, open label, and parallel controled experiment. 45 patients are selected and sign consent forms, then divided into three groups. Doctors collect the basic information of patient (including age,height, mental condition, vital sign, history of disease, pharmaco-history, genotype test, and so on.) All patients receive laboratory and image examination as baseline. Then, they will give cell treatment based on the clinical protocol. Doctors have follow-up visit on 1, 2, 3, 6, and 12 months after treatment, and do efficacy evaluation.
This is a random, open label, and parallel controled experiment. 45 patients are selected and sign consent forms, then divided into three groups. Doctors collect the basic information of patient (including age,height, mental condition, vital sign, history of disease, pharmaco-history, genotype test, and so on.) All patients receive laboratory and image examination as baseline. Then, they will give cell treatment based on the clinical protocol. Doctors have follow-up visit on 1, 2, 3, 6, and 12 months after treatment, and do efficacy evaluation.
Status Flow
Change History
16 versions recorded-
Apr 28, 2026 — Present [daily]
Not Yet Recruiting
Phase: PHASE2 → None
-
Jan 2026 — Apr 2026 [monthly]
Not Yet Recruiting PHASE2
-
May 2025 — Jan 2026 [monthly]
Not Yet Recruiting PHASE2
-
Sep 2024 — May 2025 [monthly]
Not Yet Recruiting PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Not Yet Recruiting PHASE2
▶ Show 11 earlier versions
-
May 2024 — Jul 2024 [monthly]
Not Yet Recruiting PHASE2
-
May 2023 — May 2024 [monthly]
Not Yet Recruiting PHASE2
-
Nov 2022 — May 2023 [monthly]
Not Yet Recruiting PHASE2
-
Jun 2022 — Nov 2022 [monthly]
Not Yet Recruiting PHASE2
-
Apr 2022 — Jun 2022 [monthly]
Not Yet Recruiting PHASE2
-
Mar 2022 — Apr 2022 [monthly]
Not Yet Recruiting PHASE2
-
Jan 2021 — Mar 2022 [monthly]
Not Yet Recruiting PHASE2
-
Nov 2020 — Jan 2021 [monthly]
Not Yet Recruiting PHASE2
Status: Unknown Status → Not Yet Recruiting
-
Jan 2020 — Nov 2020 [monthly]
Unknown Status PHASE2
Status: Not Yet Recruiting → Unknown Status
-
Jun 2018 — Jan 2020 [monthly]
Not Yet Recruiting PHASE2
-
Jan 2018 — Jun 2018 [monthly]
Not Yet Recruiting PHASE2
First recorded
Eligibility Summary
The purpose of this study is verify the safety and efficacy of Human Umbilical Cord Mesenchymal Stem Cells (UC-MSC) therapy for patients with Spinocerebellar Ataxia, and in addition, explore the possible mechanisms of UC-MSC therapy in Spinocerebellar Ataxia.
Contact Information
- Sclnow Biotechnology Co., Ltd.
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
No location information available.